Marriott Bethesda Downtown, MD
December 1, 2022
Multiplex quantification of protein/peptide hormones and biomarkers involved in obesity and diabetes will facilitate translational scientific research. Unfortunately, most assays today rely exclusively on antibodies and often there are no widely accepted guidelines or standardized methods to determine the validity of these reagents. Furthermore, many recent publications have highlighted the limitations of many commercial antibodies including failure to detect the intended target. The rigor and reproducibility of many assays commonly used by researchers in the field of diabetes and obesity could be substantially improved applying Mass Spectrometry (MS) instead of relying only on antibodies. Within last decade, major improvements in instrumentation and data handling have made MS–based targeted proteomics a highly reproducible methodology for detecting and quantifying proteins and peptides.
The NIDDK recently funded several projects that aim to use targeted MS approaches for quantifying human plasma/serum proteins and peptides of main interest to the obesity and diabetes research community.
This meeting will focus on advances made by the TArgeted Mass spectrometry Assays for Diabetes and Obesity Research (TAMADOR) pseudo-consortium and possible future directions. This includes insulin, pro-insulin, c-peptide, glucagon, adiponectin, leptin, secretin, and GLP-1, to name a few.
WHEN: December 1, 2022
WHERE: Marriott Bethesda Downtown at Marriott HQ | website »
7707 Woodmont Avenue, Bethesda, Maryland, USA, 20814 | map »
Tel: +1 301-276-7707
Book your group rate for The Cedars-Sinai Obesity Grant Meeting Room Block
Event Summary:
Start Date: Wednesday, November 30, 2022 3:30PM-6:00PM
Location: Marriott Grand Ballroom
Thursday, December 1, 2022
Location: Marriott Grand Ballroom
End Date: Friday, December 2, 2022
Hotel(s) offering your special group rate:
Marriott Bethesda Downtown at Marriott HQ for 199 USD per night
Book your group rate for The Cedars-Sinai Obesity Grant Meeting Room Block
ZOOM OPTION: This meeting will be in-person but the option to participate remotely via Zoom will be provided to all registered participants the day before the meeting.
NOTE: COVID Protocol: CDC, Montgomery County Info Portal, County Policy, and Hotel regulations and guidance will be followed. Masks optional but recommended. Subject to change without notice.
For logistic questions contact:
Kim Douglas
Kim.douglas@cshs.org
TEL: (310) 654-3947
For scientific content contact:
Dr. Salvatore Sechi
Sechi@nih.gov
TEL: (301)-594-8814
Pre-Meeting
November 30, 2022
3:30PM-6:00PM
Location: Marriott Grand Ballroom
18:30 Dinner in Bethesda (TaMADOR Investigators, NIDDK, Advisory panel members), Location: TBD
December 1, 2022
Location: Marriott Grand Ballroom
7:30-8:00 Coffee and Registration
8:00-8:15 Introduction and Logistics by Dr. Salvatore Sechi, NIDDK
8:15-8:25 Welcome and meeting opening by Dr. William Cefalu, Director DEM, NIDDK
8:25-9:10 Keynote Speaker - Mari Demarco, Ph.D., University of British Columbia
Session I: Targeted Mass Spectrometric Assays in Type 1 Diabetes
09:10-09:30 A novel assay to assess the endogenous role of glucagon in glucose homeostasis
Jess Becker, MLS(ASCP), M.S., University of Washington (15’ talks + 5’ Q&A)
09:30-09:50 Using novel antibodies for the measurement of pro-insulin in serum
Michelle Emrick, Ph.D., University of Washington (15’ talks + 5’ Q&A)
9:50-10:10 Coffee Break
10:10-10:40 Keynote Speaker - David A. D'Alessio, MD, Duke University
10:40-11:10 Development and transferability of a combined C-peptide and insulin assay for the study of diabetes.
Andy Hoofnagle, MD/PhD, University of Washington (25’ talks + 5’ Q&A)
11:10-11:30 A vendor neutral platform for sharing interlaboratory data to accelerate diabetes and obesity research.
Mike MacCoss, Ph.D., University of Washington (15’ talks + 5’ Q&A)
11:30-12:50 Lunch Break (on your own)
Session II: Targeted Mass Spectrometric Assays in Obesity Research
12:50-13:20 Keynote Speaker - Rudolph Leibel, MD, Columbia University
13:30-13:50 Health surveillance assay: 60 protein targeted assays for monitoring disease co-morbidities.
Annie Moradian, PhD, Cedars-Sinai Medical Center (15’ talks + 5’ Q&A)
13:50-14:10 Quantitation of proteolyzed peptide hormones involved in the regulation of obesity and diabetes.
Simion Kreimer, PhD, Cedars-Sinai Medical Center (15’ talks + 5’ Q&A)
14:10-14:30 A multiplexed immunoaffinity-MS assay for sensitive detection of adiponectin, leptin, and resistin in obesity samples.
Jie Pu, Ph.D., University at Buffalo
14:30-14:50 Coffee Break
14:50-15:10 A highly multiplexed assay for quantifying a panel of 42 obesity-associated markers in blood plasma/serum.
Tai-Du Lin, Ph.D., Pacific Northwest National Laboratory (15’ talks + 5’ Q&A)
15:10-15:30 Novel methods for the detection of low abundance markers in serum without the need of antibody reagents.
Wei-Jun Qian, Ph.D., Pacific Northwest National Laboratory,
and Jun Qu, Ph.D., University at Buffalo (15’ talks + 5’ Q&A)
15:30-16:30 Discussion on clinical translation of Mass Spectrometry based assays.
Panelists: Jennifer Van Eyk (Cedars-Sinai Medical Center), Kimia Sobhani (Cedars-Sinai Medical Center), Michael MacCoss (University of Washington), Andy Hoofnagle (University of Washington), Weijun Qian (PNNL), Jun Qu (University at Buffalo).
Introduction and moderation by Ravinder Singh (Mayo Clinic)
16:30 Meeting Adjourned
16:30-17:30 Meeting for PIs, NIDDK , and advisors only. (Grand Ballroom)
Advisors: Randie Little, University of Missouri; David Nathan, Harvard
Medical School; Rudolph Leibel, Columbia University; Philipp Sherer, UT
Southwestern (not present at this meeting); James Delany, Advent Health
Research Institute; Ravinder Singh, Mayo Clinic; Robert Fitzgerald, UCSD.
